The dermatology drugs market would grow at a CAGR of 8.91% over the predicted time frame. The market is expected to increase in value from US$ 20.1 Bn in 2022 to US$ 39.78 Bn in 2030.
The on dermatology drugs Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.
Download Free Sample@ https://www.precedenceresearch.com/sample/2414
A recent report provides crucial insights along with application based and forecast information in the Global Dermatology drugs Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Dermatology drugs market.
A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.
Companies and Manufacturers Covered
The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Dermatology drugs market are included as given below:
Dermatology drugs Market Key Players
- LUPIN (India)
- Novartis AG (Switzerland)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc. (U.S.)
- Sanofi (France)
- Amgen inc. (U.S.)
- Lilly (U.S.)
- AstraZeneca (U.K.)
- AbbVie Inc (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- LEO Pharma A/S (Denmark)
- Merck & Co., Inc (U.S.)
- Bausch Health Companies Inc (Canada)
- Bristol-Myers Squibb Company (U.S.)
Market Segments
By Indication
- Acne
- Psoriasis
- Rosacea
- Alopecia
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Administration Analysis
- Topical Administration
- Oral Administration
- Parenteral Administration
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Report Objectives
- To define, describe, and forecast the global dermatology drugs market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the dermatology drugs market
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Dermatology Drugs Market
5.1. COVID-19 Landscape: Dermatology Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Dermatology Drugs Market, By Indication
8.1. Dermatology Drugs Market, by Indication, 2022-2030
8.1.1 Acne
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Psoriasis
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Rosacea
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Alopecia
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Dermatology Drugs Market, By Distribution Channel
9.1. Dermatology Drugs Market, by Distribution Channel, 2022-2030
9.1.1. Hospital Pharmacies
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Retail Pharmacies
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Online Pharmacies
Chapter 10. Global Dermatology Drugs Market, By Administration Analysis
10.1. Dermatology Drugs Market, by Administration Analysis, 2022-2030
10.1.1. Topical Administration
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Oral Administration
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Parenteral Administration
Chapter 11. Global Dermatology Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Indication (2017-2030)
11.1.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.3. Market Revenue and Forecast, by Administration Analysis (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Indication (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.4.3. Market Revenue and Forecast, by Administration Analysis (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Indication (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Administration Analysis (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Indication (2017-2030)
11.2.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.3. Market Revenue and Forecast, by Administration Analysis (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Indication (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.4.3. Market Revenue and Forecast, by Administration Analysis (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Indication (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Administration Analysis (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Indication (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Administration Analysis (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Indication (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Administration Analysis (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Indication (2017-2030)
11.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.3. Market Revenue and Forecast, by Administration Analysis (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Indication (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.4.3. Market Revenue and Forecast, by Administration Analysis (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Indication (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Administration Analysis (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Indication (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Administration Analysis (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Indication (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Administration Analysis (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Indication (2017-2030)
11.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.3. Market Revenue and Forecast, by Administration Analysis (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Indication (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.4.3. Market Revenue and Forecast, by Administration Analysis (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Indication (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Administration Analysis (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Indication (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Administration Analysis (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Indication (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Administration Analysis (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Indication (2017-2030)
11.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.3. Market Revenue and Forecast, by Administration Analysis (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Indication (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.4.3. Market Revenue and Forecast, by Administration Analysis (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Indication (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Administration Analysis (2017-2030)
Chapter 12. Company Profiles
12.1. LUPIN (India)
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Novartis AG (Switzerland)
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. F. Hoffmann-La Roche Ltd (Switzerland)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Pfizer Inc. (U.S.)
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Sanofi (France)
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Amgen inc. (U.S.)
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Lilly (U.S.)
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. AstraZeneca (U.K.)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. AbbVie Inc (U.S.)
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Johnson & Johnson Private Limited (U.S.)
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments